VIA EMAIL ONLY January 26, 2018 Kerry Propper Chief Executive Officer Chardan Capital Markets, LLC

Exhibit 10.2

 

 

 

 

 

VIA EMAIL ONLY

 

January 26, 2018

 

▇▇▇▇▇ ▇▇▇▇▇▇▇

Chief Executive Officer

Chardan Capital Markets, LLC

▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇

New York, NY 10004

 

Re: Mutual Termination Agreement

 

Dear ▇▇. ▇▇▇▇▇▇▇:

 

This letter is to confirm that PharmaCyte Biotech, Inc. (“Company”) and Chardan Capital Markets, LLC (“Chardan”) have agreed to mutually terminate the letter agreement between Chardan Capital Markets, LLC (“Chardan”) and the Company dated May 28, 2014, as amended on December 15, 2016 (collectively, “Engagement Agreement”). Chardan agrees that no further fees or warrants are due and payable by the Company to Chardan pursuant to the Engagement Agreement.

 

 

	Sincerely,
	/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
	Chief Executive Officer
	President and General Cousel

 

 

Acknowledged and Agreed

 

Chardan Capital Markets, LLC

 

 

By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇                 

Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇

Title: Managing Director